JP2015531371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531371A5 JP2015531371A5 JP2015534463A JP2015534463A JP2015531371A5 JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5 JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- heteroaryl
- aryl
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- -1 CF 3 Inorganic materials 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000004221 bone function Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707661P | 2012-09-28 | 2012-09-28 | |
| US61/707,661 | 2012-09-28 | ||
| PCT/US2013/032588 WO2014051698A1 (en) | 2012-09-28 | 2013-03-15 | Fused heterocyclic compounds as selective bmp inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531371A JP2015531371A (ja) | 2015-11-02 |
| JP2015531371A5 true JP2015531371A5 (enExample) | 2016-05-12 |
| JP6430383B2 JP6430383B2 (ja) | 2018-11-28 |
Family
ID=50388847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534463A Expired - Fee Related JP6430383B2 (ja) | 2012-09-28 | 2013-03-15 | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9738636B2 (enExample) |
| EP (1) | EP2900238B1 (enExample) |
| JP (1) | JP6430383B2 (enExample) |
| KR (1) | KR102092988B1 (enExample) |
| CN (1) | CN104768548B (enExample) |
| AU (1) | AU2013324396B2 (enExample) |
| BR (1) | BR112015007136A2 (enExample) |
| CA (1) | CA2886187C (enExample) |
| DK (1) | DK2900238T3 (enExample) |
| ES (1) | ES2660051T3 (enExample) |
| SG (1) | SG11201503299YA (enExample) |
| WO (1) | WO2014051698A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773213B (zh) | 2010-09-01 | 2023-02-24 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| HK1256753A1 (zh) | 2015-08-11 | 2019-10-04 | Neomed Institute | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| ES2963348T3 (es) | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| KR102359707B1 (ko) * | 2016-07-20 | 2022-02-09 | 노파르티스 아게 | 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 |
| WO2018053126A1 (en) | 2016-09-14 | 2018-03-22 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| US20200054643A1 (en) * | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2019178383A1 (en) * | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| CN110496127A (zh) * | 2018-05-17 | 2019-11-26 | 中国科学院上海生命科学研究院 | 一种热休克因子1的抑制剂、其制备方法和应用 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| JP7414827B2 (ja) * | 2018-12-20 | 2024-01-16 | インサイト・コーポレイション | アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| TW202131926A (zh) | 2019-11-22 | 2021-09-01 | 美商英塞特公司 | 包含alk2抑制劑及jak2抑制劑的組合療法 |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| IL298767A (en) | 2020-06-16 | 2023-02-01 | Incyte Corp | ALK2 inhibitors for the treatment of anemia |
| WO2024205336A1 (ko) * | 2023-03-30 | 2024-10-03 | 에이치엘비생명과학알앤디 주식회사 | 튜블린 저해 활성을 갖는 약학적 조성물 |
| AU2023449758A1 (en) * | 2023-05-22 | 2025-12-11 | Iregene Therapeutics Co., Ltd | Use of bmpr1b inhibitor in induced induction of development, and induction culture medium |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2562071B1 (fr) * | 1984-03-30 | 1986-12-19 | Sanofi Sa | Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| JP4747396B2 (ja) | 2000-05-17 | 2011-08-17 | 日立化成工業株式会社 | 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造 |
| BR0207096A (pt) * | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| US7125888B2 (en) * | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| EP2086973B1 (en) * | 2006-10-11 | 2012-01-25 | Amgen Inc., | Imidazo- and triazolo-pyridine compounds and methods of use therof |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| JP2010522765A (ja) * | 2007-03-28 | 2010-07-08 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物 |
| UA101611C2 (ru) * | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
| WO2009002534A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| KR101150581B1 (ko) * | 2007-07-26 | 2012-06-11 | 노파르티스 아게 | 유기 화합물 |
| EA201000615A1 (ru) * | 2007-10-17 | 2010-12-30 | Новартис Аг | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| GB0810902D0 (en) * | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2009157423A1 (ja) * | 2008-06-24 | 2009-12-30 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
| US8592425B2 (en) | 2009-01-16 | 2013-11-26 | Merck Sharp & Dohme Corp. | Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| JPWO2011136264A1 (ja) | 2010-04-28 | 2013-07-22 | 第一三共株式会社 | ［５，６］複素環化合物 |
| WO2011137155A1 (en) * | 2010-04-28 | 2011-11-03 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US9505763B2 (en) | 2011-07-25 | 2016-11-29 | Vanderbilt University | Cancer treatment using BMP inhibitor |
| EP2615151A1 (en) | 2011-12-23 | 2013-07-17 | Services Pétroliers Schlumberger | Compositions and methods for well cementing |
| EP2964651A4 (en) * | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
| JP6542192B2 (ja) | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害剤およびその使用方法 |
-
2013
- 2013-03-15 JP JP2015534463A patent/JP6430383B2/ja not_active Expired - Fee Related
- 2013-03-15 CA CA2886187A patent/CA2886187C/en not_active Expired - Fee Related
- 2013-03-15 DK DK13840866.1T patent/DK2900238T3/en active
- 2013-03-15 EP EP13840866.1A patent/EP2900238B1/en not_active Not-in-force
- 2013-03-15 AU AU2013324396A patent/AU2013324396B2/en not_active Ceased
- 2013-03-15 WO PCT/US2013/032588 patent/WO2014051698A1/en not_active Ceased
- 2013-03-15 BR BR112015007136A patent/BR112015007136A2/pt not_active IP Right Cessation
- 2013-03-15 SG SG11201503299YA patent/SG11201503299YA/en unknown
- 2013-03-15 US US14/432,472 patent/US9738636B2/en not_active Expired - Fee Related
- 2013-03-15 CN CN201380058849.8A patent/CN104768548B/zh not_active Expired - Fee Related
- 2013-03-15 ES ES13840866.1T patent/ES2660051T3/es active Active
- 2013-03-15 KR KR1020157011027A patent/KR102092988B1/ko not_active Expired - Fee Related
-
2017
- 2017-07-17 US US15/652,100 patent/US10196392B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519467A5 (enExample) | ||
| JP2017538677A5 (enExample) | ||
| RU2021115958A (ru) | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы | |
| JP2017537080A5 (enExample) | ||
| JP2019500315A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| EP3133074A3 (de) | 7-azaindolderivate | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2012515776A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2009529540A5 (enExample) | ||
| JP2012006912A5 (ja) | トリアゾール誘導体 | |
| JP2016526540A5 (enExample) | ||
| JP2012140436A5 (ja) | 物質 | |
| JP2014524441A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2018135343A5 (enExample) |